Millipore at neutral by Merrill

Millipore Corp. was rated at neutral by Merrill Lynch analyst Darryl Pardi on the company's financially attractive acquisition of Serologicals Corp. Millipore's first-quarter earnings per share fell 4% to $0.74, 2 cents below Merrill's forecast. Shares of the Billerica, Mass., biopharmaceutical products company were down $2.08, or 2.76%, at $73.17 on volume of 699,400 shares versus the three-month running average of 355,221 shares. (NYSE: MIL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.